Intellia Therapeutics, Inc.
NTLANASDAQHealthcare● Active
$13.54
+$0.00(+0.04%)
Market Cap$1.5B
P/E Ratio—
52W High$28.25
52W Low$7.31
Intellia Therapeutics, Inc.（NTLA）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · NTLA · 截至 2026-06-08
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $67.67M | $57.88M | $36.27M | $52.12M | $33.05M |
| Cost of Revenue | $15.92M | $10.29M | $8.98M | $7.57M | $6.89M |
| Gross Profit | $51.75M | $47.59M | $27.30M | $44.55M | $26.16M |
| Gross Margin %(computed) | 76.47% | 82.23% | 75.26% | 85.47% | 79.15% |
| Operating Expenses | |||||
| R&D Expenses | $388.86M | $466.31M | $435.07M | $419.98M | $229.81M |
| G&A Expenses | $119.80M | $125.83M | $116.50M | $90.31M | $71.10M |
| Total Operating Expenses | $492.74M | $581.86M | $542.59M | $502.71M | $294.01M |
| Operating Income | ($440.99M) | ($534.26M) | ($515.29M) | ($458.16M) | ($267.85M) |
| Operating Margin %(computed) | -651.67% | -923.10% | — | -879.04% | -810.37% |
| Interest Income | $29.20M | $47.81M | $49.83M | $8.54M | $1.28M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($412.69M) | ($519.02M) | ($481.19M) | ($474.19M) | ($267.89M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($412.69M) | ($519.02M) | ($481.19M) | ($474.19M) | ($267.89M) |
| Net Margin %(computed) | -609.85% | -896.77% | — | -909.78% | -810.49% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.81 | $-5.25 | $-5.42 | $-6.16 | $-3.78 |
| Wtd Avg Shares | 108.38M | 98.85M | 88.77M | 76.97M | 70.89M |
| EBITDA | ($396.77M) | ($523.98M) | ($506.31M) | ($450.59M) | ($260.96M) |
| EBITDA Margin %(computed) | -586.32% | -905.33% | — | -864.51% | -789.52% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-08 · USD · M
深入了解Intellia Therapeutics, Inc.
关于Intellia Therapeutics, Inc.（NTLA）损益表
Intellia Therapeutics, Inc.（NTLA）损益表数据来源于SEC Form 10-K及10-Q申报文件。2025财年，NTLA实现营收$0.07B，毛利润$0.05B（毛利率76.47%），净利润($0.41B)（净利率-609.85%）。
常见问题
NTLA · 4 问Intellia Therapeutics, Inc.（NTLA）2025财年营收为$0.07B，同比up16.9%。
NTLA revenueNTLA salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08